RIXS STUDIES OF PLATINUM COMPLEXES FOR CANCER THERAPY

RIXS 对铂复合物用于癌症治疗的研究

• 批准号: 7721953
• 负责人: SERENA D DE BEER GEORGE
• 金额: $ 0.52万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7721953
• 关键词: Antineoplastic Agents; Cancerous; Cells; Chemicals; Cisplatin; Complex; Computer Retrieval of Information on Scientific Projects Database; Environment; Funding; Future; Grant; Institution; Malignant neoplasm of cervix uteri; Ovarian; Platinum; Research; Research Personnel; Resources; Solutions; Source; Structure; Toxic effect; United States National Institutes of Health; cancer therapy; cancer type; improved; solid solution; streptidine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cisplatin (cis-[PtCl2(NH3)2])) is one of the most widely used anticancer drugs and has been shown to be an effective treatment for ovarian, testicular and cervical cancers. However, despite the fact that it is highly effective in treating several types of cancer; cisplatin is also toxic and there are many types of cancer that it does not effectively target. In an effort to improve treatment, much research has focused on synthesizing different type of Pt complexes with reduced toxicity, increased activity, and the ability to be administered orally. Many of these small chemical compounds can be crystallized and characterized by diffraction studies. However, in order to understand the mechanism of these complexes, an understanding of the solution structure is vital. Recently we have used Pt L3-edge XAS to characterize solid and solution structures of Pt anticancer agents, including Pt-Streptidine. Future studies will include examination of the Pt coordination environment within cancerous cells.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 顺铂(cis-[PtCl2(NH3)2])是目前应用最广泛的抗癌药物之一，已被证明是治疗卵巢癌、睾丸癌和宫颈癌的有效药物。然而，尽管顺铂在治疗几种类型的癌症方面非常有效，但它也是有毒的，而且有许多类型的癌症没有有效的靶向。为了改善治疗，许多研究集中在合成不同类型的铂配合物，这些配合物具有毒性低、活性高和能够口服的特点。这些小化合物中的许多都可以结晶，并通过衍射研究进行表征。然而，为了了解这些络合物的机理，了解溶液结构是至关重要的。最近，我们用铂L3边XAS表征了铂抗癌剂的固体和溶液结构，包括铂-链氨酸。未来的研究将包括检查癌细胞内的铂配位环境。